Skip to content

Study · Non-randomized trial · n = 24 · 2010

2 results

Immunological modifications during treatment with thymosin alpha1 plus antiviral therapy in chronic hepatitis C.

Grandini E, Cannoletta F, Scuteri A, Fortini C, Loggi E, Cursaro C, Riili A, Di Donato R, Gramenzi A, Bernardi M, Andreone P

Annals of the New York Academy of Sciences1 Apr 2010Cited by 3 (Europe PMC)

PMID20536463 (opens in a new tab)DOI10.1111/j.1749-6632.2010.05461.x (opens in a new tab)PepBankPUB-20536463
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with chronic hepatitis C who did not respond to peginterferon-based therapy, adding Talpha1 to standard antiviral therapy did not significantly change T-lymphocyte subpopulations.

    In plain wordsIn people with hepatitis C, adding thymosin alpha‑1 to standard treatment did not clearly change T-cell groups compared with standard treatment alone.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeT-lymphocyte subpopulations
    Study

    n = 24

    Comparator
    Standard antiviral therapy without Talpha1
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Although the addition of Talpha1 did not seem to significantly modify the T-lymphocyte subpopulations, as comparable behaviors were observed in the CD4 and CD8 longitudinal evaluation
    1 context sentence
    Summary · context
    The aim of this study was to evaluate, in patients nonresponsive to previous Peg-based therapy, the effect of standard antiviral therapy with or without Talpha1 on peripheral lymphocyte subsets. Twenty-four patients, 12 receiving Talpha1 and 12 standard therapy, were enrolled. Peripheral subpopulati…
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with chronic hepatitis C, adding Talpha1 to standard antiviral therapy produced an earlier increase of natural killer cells than standard therapy alone.

    In plain wordsIn people with hepatitis C, adding thymosin alpha‑1 to standard treatment led to an earlier rise in natural killer cells than standard treatment alone.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseNatural killer cell count
    Study

    n = 24

    Comparator
    Standard antiviral therapy without Talpha1
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Talpha1 produced an earlier increase of natural killer cells.
    1 context sentence
    Summary · context
    The aim of this study was to evaluate, in patients nonresponsive to previous Peg-based therapy, the effect of standard antiviral therapy with or without Talpha1 on peripheral lymphocyte subsets. Twenty-four patients, 12 receiving Talpha1 and 12 standard therapy, were enrolled. Peripheral subpopulati…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.